Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Bionic eye implant aims to restore sight in dry AMD patients

NCT ID NCT03392324

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This early feasibility trial tests a new retinal implant called PRIMA in 5 people with advanced dry age-related macular degeneration who have lost central vision. The device is surgically placed in the eye to stimulate remaining retinal cells. Researchers are checking if it is safe and whether it can improve near vision and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PRIMA retinal implant (device)
What this could lead to
If it works, this could point toward a way to restore some vision in people with advanced dry age-related macular degeneration.
What could go wrong
This is a very early, small trial with only 5 participants. The implant may not improve vision enough to be useful, and surgery carries risks like infection or device failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5 people

The number who actually took part.

Started

Apr 2018

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is 60 years or older at the date of inclusion; * Has a confirmed diagnosis of atrophic dry age related macular degeneration with an atrophy size of at least 3 optic disc diameters in the study eye; * Has best corrected visual acuity of logMAR 1.3 (20/400) or worse in the study eye measured by ETDRS; * Has a central scotoma in the study eye with no perception at 0 dB on MP-1 micro-perimetry scale in the visual field covering the central 7 degrees (+/-3.5 degrees) and maximum 20% perception in the remaining visual field covering the central 12 degrees (+/- 6 degrees); * Meets one of the following criteria in the non-study eye: * Visual acuity of 20/200 (logMAR 1.0) or worse and an atrophy size \<8mm2 * Visual acuity of 20/160 (logMAR 0.9) or worse and an atrophy size ≥8mm2 and ≤12.5 mm2 * Visual acuity of 20/100 (logMAR 0.7) or worse and an atrophy size \>12.5 mm2 * Has a refraction of study eye between -3 and + 4 (limits included) for patients with IOL (there is no refraction criteria for phakic patients); * Understands and accepts the obligation to present for all schedule follow-up visits; * Patient signed informed consent. Main Exclusion Criteria: * Has cataract in the study ; * Has an aphakic study eye; * Has no light perception in the study eye; * Has a history of choroidal neovascularization in either eye; * Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye * Has an implanted telescope in one eye; * Has any disease or condition that prevents adequate examination of the study * Has a corneal endothelial cell count of less than 1000 cells/mm² in the study eye * Suffers from nystagmus or other ocular motility disorders; * Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols * Has a history of epileptic seizure; * Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study; * Presents with hypotony or hypertony in the study eye; * Has another active implanted device; * Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis; * Is an immune-suppressed subject; * Is carrier of multi-resistant microorganisms; * Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery; * Is participating in another investigational drug or device study that may interfere with the present study; * Has recurrent or chronic inflammations or infections; * Has a severe psychological disorder; * Does not have the mental capacity to legally sign the informed consent; * Has severe renal, cardiac, hepatic, etc. organ diseases; * Has head dimensions that are incompatible with the Visual Interface; * Has too high and unrealistic expectation; Detailed patient criteria will be verified by the study doctor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bascom Palmer Eye Institute

    Miami, Florida, 33136, United States

  • Byers Eye Institute-Stanford University

    Palo Alto, California, 94303, United States

  • UPMC Eye Center

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.